Stopping trials for benefit can (sometimes) benefit patients

Journal of Clinical Oncology

Volumn 26, Issue 16, 2008, Pages 2787-2788

  Pater, Joseph L ^a   Goss, Paul ^b   Meyer, Ralph ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LETROZOLE; PLACEBO;

CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CORRELATION ANALYSIS; HUMAN; LETTER; OUTCOME ASSESSMENT; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT DURATION; ETHICS; NOTE; PROFESSIONAL STANDARD; TIME; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS DATA MONITORING COMMITTEES; HUMANS; TIME FACTORS; TREATMENT OUTCOME;

EID: 45749142526     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.1785     Document Type: Letter

References (6)

1. Wilcox RA, Djulbegovic BJ, Guyatt GH, et al: Randomized trials in oncology stopped early for benefit. J Clin Oncol 26:18-19, 2008
2. Montori VM, Devereaux PJ, Adhikari NK, et al: Randomized trials stopped early for benefit: A systematic review. JAMA 294:2203-2209, 2005
3. Pocock SJ: When (not) to stop a clinical trial for benefit. JAMA 294:2228-2230, 2005
4. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003
5. Goss PE, Ingle JN, Martino S, et al: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor positive breast cancer: Updated findings from NCIC CTG MA. 17. J Natl Cancer Inst 97:1262-1271, 2005
6. Ingle JN, Tu D, Pater JL, et al: Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 99:295-300, 2006